CA3243024A1 - Methodes et traitement de la maladie de still chez l'adulte et de la forme systemique de l'arthrite idiopathique juvenile impliquant des anticorps diriges contre il-18 - Google Patents

Methodes et traitement de la maladie de still chez l'adulte et de la forme systemique de l'arthrite idiopathique juvenile impliquant des anticorps diriges contre il-18

Info

Publication number
CA3243024A1
CA3243024A1 CA3243024A CA3243024A CA3243024A1 CA 3243024 A1 CA3243024 A1 CA 3243024A1 CA 3243024 A CA3243024 A CA 3243024A CA 3243024 A CA3243024 A CA 3243024A CA 3243024 A1 CA3243024 A1 CA 3243024A1
Authority
CA
Canada
Prior art keywords
ser
antibody
thr
gly
vai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3243024A
Other languages
English (en)
Inventor
Garry A. Neil
H. Jeffrey WILKINS
Original Assignee
Avalo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalo Therapeutics Inc filed Critical Avalo Therapeutics Inc
Publication of CA3243024A1 publication Critical patent/CA3243024A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3243024A 2021-12-20 2021-12-20 Methodes et traitement de la maladie de still chez l'adulte et de la forme systemique de l'arthrite idiopathique juvenile impliquant des anticorps diriges contre il-18 Pending CA3243024A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/064357 WO2023121643A1 (fr) 2021-12-20 2021-12-20 Méthodes et traitement de la maladie de still chez l'adulte et de la forme systémique de l'arthrite idiopathique juvénile impliquant des anticorps dirigés contre il-18

Publications (1)

Publication Number Publication Date
CA3243024A1 true CA3243024A1 (fr) 2025-02-26

Family

ID=86903549

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3243024A Pending CA3243024A1 (fr) 2021-12-20 2021-12-20 Methodes et traitement de la maladie de still chez l'adulte et de la forme systemique de l'arthrite idiopathique juvenile impliquant des anticorps diriges contre il-18

Country Status (6)

Country Link
JP (1) JP2025500352A (fr)
KR (1) KR20240134909A (fr)
AU (1) AU2021479973A1 (fr)
CA (1) CA3243024A1 (fr)
MX (1) MX2024007616A (fr)
WO (1) WO2023121643A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255144B2 (en) * 2010-12-20 2016-02-09 Medimmune Limited Anti-IL-18 antibodies and their uses
CA2972689A1 (fr) * 2015-03-05 2016-09-09 Ab2 Bio Sa Proteine de liaison a l'il-18 (il-18 bp) et anticorps dans des maladies inflammatoires

Also Published As

Publication number Publication date
WO2023121643A1 (fr) 2023-06-29
KR20240134909A (ko) 2024-09-10
MX2024007616A (es) 2024-09-04
AU2021479973A1 (en) 2024-07-04
JP2025500352A (ja) 2025-01-09

Similar Documents

Publication Publication Date Title
US10363307B2 (en) Methods of treating psoriatic arthritis using IL-17 antagonists
US20250066466A1 (en) Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
JP6904905B2 (ja) 抗α４β７インテグリン抗体による治療の結果の予測
JP2022023051A (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
TW201100446A (en) Use of TNFα inhibitor for treatment of erosive polyarthritis
JP2020100631A (ja) 多発性硬化症の併用治療
US20230279095A1 (en) Methods and Treatment for Adult-Onset Still's Disease and Systemic-Onset Juvenile Idiopathic Arthritis Involving Antibodies to IL-18
US20230122171A1 (en) Use of Brazikumab to Treat Crohn's Disease
JP7497159B2 (ja) 慢性回腸嚢炎の治療のための方法
CA3243024A1 (fr) Methodes et traitement de la maladie de still chez l'adulte et de la forme systemique de l'arthrite idiopathique juvenile impliquant des anticorps diriges contre il-18
US20230203150A1 (en) Methods and Treatment Involving Antibodies to IL-18
TW202325730A (zh) 涉及ｉｌ－１８抗體之成人史迪爾氏症（ｓｔｉｌｌ＇ｓ ｄｉｓｅａｓｅ）及全身性幼年特發性關節炎之方法及治療
KR20190142398A (ko) Il-17 길항제를 사용하여 천식을 선택적으로 치료하는 방법
KR20220087537A (ko) C5 관련 질환을 치료 또는 예방하기 위한 투여 요법
TW202323290A (zh) 涉及il-18抗體之方法及治療
US20250002598A1 (en) Methods of Treating Asthma with Anti-LIGHT Antibodies
US20240301074A1 (en) Use of anti-il-36r antibodies for the treatment of hidradentitis suppurativa (hs)
US11708406B2 (en) Method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) associate with COVID-19 by administering an anti-LIGHT antibody
RU2822135C2 (ru) Способы лечения хронического резервуарного илеита
WO2023107100A1 (fr) Procédés et traitement pour le myélome multiple mettant en œuvre des anticorps dirigés contre il-18
Tweehuysen et al. Subjective Complaints as Main Reason for Biosimilar Discontinuation after Open Label Transitioning from Originator to Biosimilar Infliximab
JP2019089840A (ja) コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240704

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: FIRST IPC ASSIGNED

Effective date: 20240704

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20240704

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC ASSIGNED

Effective date: 20240704

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20240718

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250120

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250120

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20250226